HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Biotechnology

Pharmaceutical

Therapeutics

HUYABIO International

Christopher Kemmerer

Sungwoo Ahn

Kelsee Dauz

Holly Jing

Francesco Santo

Hao L.

Rick Witte

Farbod Shojaei

Nicola Dowling

Ivan O'Toole

Hiroshi Onogi

Jerome Riebman

Zhijun Wang

Suzanne J. Romano

Jason Wang

Gloria Lee

Clement Gingras

Alan Kholos

The Leadership Team at HUYABIO International is responsible for steering the company’s strategic vision and ensuring successful execution across all areas. This team of senior executives oversees clinical operations, preclinical drug discovery, commercial operations, financial management, quality operations, and corporate development. They collaborate closely to drive global biopharmaceutical product development, leveraging HUYABIO’s extensive China-sourced compound portfolio to achieve faster, cost-effective, and lower-risk drug development.

Leadership Team

Business Development & Operations

Executive Operations

Leadership Team

About

Team members

Other teams at HUYABIO International

Business Development & Operations

Executive Operations